A Friday meeting in Washington got a little messy: An expert panel said the Food and Drug Administration (FDA) shouldn’t green-light Pfizer’s COVID-19 booster shot for the general public — but not without some dissent.Pfizer executive Dr. William Gruber argued that without booster shots the US could face a wave of infections among the vaccinated. But committee members questioned whether it was too soon to tell if boosters offer any more protection to healthy Americans who’ve already received two
https://www.businessinsider.com/how-pfizer-and-moderna-measure-vaccine-effectiveness-2021-9
